Reducing heart damage and improving function after a heart attack using targeted drugs.
Minimizing myocardial damage and loss of cardiac function post myocardial infarction using Targeted PKC inhibitors 002 and 004.
This study is testing two new heart-protecting drugs, YT-002 and YT-004, in pigs to see how well they work after a heart attack, with hopes of eventually helping people keep their hearts healthy.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Young Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11068139 on NIH RePORTER |
What this research studies
This research focuses on developing two new drugs, YT-002 and YT-004, that aim to protect heart tissue and maintain heart function after a heart attack. The study will involve testing these drugs in a pig model to understand how they work in the body and their long-term effects on heart health. Researchers will optimize the drug formulations for better stability and delivery, and conduct detailed studies to assess how the drugs are absorbed and how they affect heart function over time. The ultimate goal is to gather enough evidence to support future human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced a myocardial infarction or are at high risk for heart attacks.
Not a fit: Patients who have not had a heart attack or do not have cardiovascular issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce heart damage and improve recovery after heart attacks.
How similar studies have performed: Previous research has shown promise in using targeted therapies for cardiac protection, suggesting potential success for this approach.
Where this research is happening
Philadelphia, United States
- Young Therapeutics, LLC — Philadelphia, United States (Active)
Researchers
- Principal investigator: Young, Lindon H — Young Therapeutics, LLC
- Study coordinator: Young, Lindon H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.